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Abstract Cognitive deﬁcits are commonly observed in
stroke patients. Neuropsychological testing is time-con-
suming and not easy to administer after hospital discharge.
Standardised screening measures are desirable. The Mini-
Mental State Examination (MMSE) is the test most widely
applied to screen for cognitive deﬁcits. Despite its broad
use, its predictive characteristics after stroke have not been
exhaustively investigated. The aim of this study was to
determine whether the MMSE is able to adequately screen
for cognitive impairment and dementia after stroke and
whether or not the MMSE can predict further deterioration
or recovery in cognitive function over time. To this end, we
studied 194 ﬁrst-ever stroke patients without pre-stroke
cognitive deterioration who underwent MMSEs and neu-
ropsychological test batteries at 1, 6, 12, and 24 months
after stroke. The MMSE score 1 month after stroke pre-
dicted cognitive functioning at later follow-up visits. It
could not predict deterioration or improvement in cognitive
functioning over time. The cut-off score in the screening
for 1 cognitive disturbed domain was 27/28 with a sensi-
tivity of 0.72. The cut-off score in the screening for at least
4 impaired domains and dementia were 26/27 and 23/24
with a sensitivity of 0.82 and 0.96, respectively. The results
indicated that the MMSE has modest qualities in screening
for mild cognitive disturbances and is adequate in screen-
ing for moderate cognitive deﬁcits or dementia in stroke
patients 1 month after stroke. Poor performance on the
MMSE is predictive for cognitive impairment in the long
term. However, it cannot be used to predict further cog-
nitive deterioration or improvement over time.
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Introduction
Over half of stroke patients suffer from disturbances in
cognition such as memory problems and mental slowness.
In the acute phase after stroke, these cognitive deﬁcits
often remain unrecognised because, at that time, a patient
frequently is not fully aware of possible cognitive dys-
function. Furthermore, a thorough neuropsychological
evaluation is not routinely administered. After a longer
period after stroke, however, cognitive impairment is
considerably prevalent [1–3]. These so called ‘invisible’
consequences can have a great negative impact on reha-
bilitation and outcome [4, 5].
Over the last decade, stroke care has become much more
efﬁcient, costs have lowered and hospital stays shortened.
Most functional recovery occurs within the ﬁrst months
after stroke, and starting a rehabilitation course in an early
stage is beneﬁcial for a patient’s outcome. Also, cogni-
tively impaired elders beneﬁt from admission to acute
stroke and rehabilitation units [6, 7]. Usually, patients
undergo physical and cognitive screening in an early stage
to arrange the most effective rehabilitation program after
hospital discharge and to arrange appropriate home
adjustments. Therefore, valid screening measurements are
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stroke recovery. At that time most stroke care often is
provided by a general practitioner.
The Mini-Mental Stage Examination (MMSE) is the
instrument most widely used in screening for cognitive
problems in hospitalised patients and in outpatient settings.
It comprises thirty items providing information about ori-
entation, attention, learning, calculation, delayed recall,
and construction [8]. Several studies report acceptable
validity of the MMSE as a screening instrument and its
relationship to functional outcome in stroke patients [9–
12]. Others conclude that it is not an accurate screening
tool for cognitive deﬁcits in stroke patients, as it cannot
differentiate between focal and diffuse lesions, it is lan-
guage-, age-, and education-dependent, and it is insensitive
to right-sided lesions [13–15].
Although the value of the MMSE in the screening for
cognitive dysfunction in stroke patients is still under
debate, it is widely used and it has become a clinical
standard. It is brief and easily applicable, and has a low
interrater variability [13, 16].
The aims of this study were to see whether the MMSE is
sufﬁciently accurate in screening for mild and moderate
cognitive disturbances and to determine whether it can be
used in a two-step approach, selecting patients with no
cognitive deﬁcits from those would need thorough cogni-
tive testing by a neuropsychological test battery. It is
conceivable that patients with a poor score on the MMSE
are prone to problems with rehabilitation and further
deterioration and so would need closer follow-up. There-
fore we studied whether the MMSE in an early phase could




Between January 2000 and August 2001, 194 consecutive
patients admitted with supratentorial stroke to the Neurol-
ogy Department of the University Hospital Maastricht were
enrolled in this study. Study and patient characteristics
have been described previously [17]. Patients were asked
within 48 h after stroke to participate in the study.
All participants underwent a structured medical and
neurological assessment including medical history, physi-
cal examination, laboratory studies, and brain CT. CT was
performed on the day of admission or the day after. These
data were registered in the Maastricht Stroke Register
(MSR).
Stroke was diagnosed by a neurologist by clinical
evaluation and a brain CT scan. Inclusion criteria were a
ﬁrst hemispheral stroke, age over 40 years, adequate post-
stroke ﬂuency in Dutch, and an initial post-stroke MMSE
score [15. Exclusion criteria were severe aphasia,
pre-stroke dementia, and other major neurological or psy-
chiatric disorders that could interfere with the neuropsy-
chological testing.
Patients were followed-up 1, 6, 12, and 24 months after
the event for clinical and neuropsychological evaluation.
The study was based on informed consent and was
approved by the local medical ethics committee.
Assessment of cognitive functioning
Pre-stroke cognitive functioning was assessed by means of
a semi-structured interview with a patients’ caregiver based
on the DSM-IV diagnostic criteria for dementia. The
caregiver was asked whether the patient had memory
problems or other cognitive impairments before stroke and
how much these impairments interfered with daily living.
This interview was repeated at each assessment. However,
after the ﬁrst assessment, the focus shifted from compari-
son with pre-stroke functioning towards cognitive func-
tioning compared to the previous assessment.
Within 1 month all participants were assessed by a well-
trained neuropsychologist (SR) using the standardised
Dutch translation of the MMSE and a neuropsychological
test battery consisting of the following tests: CAMCOG,
Concept Shifting Test, Stroop Colour Word Test, Auditory
Verbal Learning test and the Groninger Intelligence Test.
This battery assesses memory, language, mental speed,
orientation, attention, praxis, executive functioning, cal-
culation, and visuospatial functioning. Cognitive func-
tioning was compared with that of a norm group from the
Maastricht Aging Study (MAAS), which investigates nor-
mal cognitive ageing in healthy older volunteers. Norm
tables are stratiﬁed according to age, sex, and educational
level [18].
A score lower than the 10th percentile of the score of the
norm group deﬁned a deﬁcit on a cognitive domain [19].
Table 1 represents the ten cognitive domains tested.
Patients were screened for disturbances in 1, 2, and at least
4 domains. These categories were chosen somewhat arbi-
trarily. Literature reports studies screening for at least 1
disturbed domain, and in another study performed by
Tatemichi et al. cognitive impairment was deﬁned as a
disturbance in at least 4 domains. [2, 20, 21].
Diagnosis of dementia was based on data including
medical history, test performance, structured information
from a patient’s informant about daily life functioning, and
clinical observation. Two experienced clinicians indepen-
dently made the diagnosis according to the DSM-IV criteria
for dementia, blind to MMSE data. The diagnosis of Vas-
cular Dementia (VaD) was based on the NINDS-AIREN
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123criteria. Agreement between the two raters was j = 0.88;
p = 0.01. If there was a discrepancy in diagnosis, a con-
sensus meeting was arranged. If consensus was not reached,
the patient was not considered to be demented.
A change in cognitive performance was deﬁned as an
improvement or deterioration in the number of cognitive
domains that were impaired.
Statistical analyses
For patient characteristics, descriptive statistics were
administered. To determine the prevalence of patients who
improved or deteriorated cognitively during the follow-up
period, only patients with complete follow-up data were
studied.
Pearson’s correlation coefﬁcients were calculated to
study a relationship between baseline MMSE scores and
MMSE scores at later follow-up visits, and between base-
line MMSE scores and the number of cognitive domains
disturbed. Spearman’s Rho was calculated to study the
relationship between baseline MMSE score and the course
of cognitive functioning at later follow-up visits.
Multivariate linear and logistic regression analyses
adjusted for age, sex, and educational level were admin-
istered to see whether baseline MMSE scores could predict
a disturbance in cognitive domains tested, whether the
MMSE could predict dementia, and whether baseline
MMSE could predict the course of cognitive functioning at
later follow-ups.
To assess a cut-off score of the MMSE in order to screen
for impairment in at least one, two and four out of ten
cognitive domains and to screen for dementia, Receiver
Operating Characteristics (ROC) curves were obtained.
The Area Under the Curve (AUC) was calculated as a
measure of the accuracy of the scale. The closer its AUC
value is to 1.0, the more accurate a test is in determining
impaired patients and non-impaired patients. Sensitivity,
speciﬁcity, and the positive predictive value were calcu-
lated at the cut-off points.
Missing data were imputed by logistic regression. Data
imputation was performed if there was another test cov-
ering the same cognitive domain available and if the
missing test was administered previously or at a later fol-
low-up.
All analyses were performed with the statistical Package
for Social Sciences version 15 (SPSS-15).
Results
Between January 2000 and June 2001, 194 ﬁrst-ever stroke
patients were included in this study. In this period, 592
patients were diagnosed as suffering from a stroke. Of these
patients, 80 died within 1 month after stroke and 363 were
excluded (89 were not ﬁrst-ever strokes, 57 had a stroke
located in the brainstem or cerebellum, 46 MMSE\15, 34
had severe aphasia, 22 had comorbid neurological or psy-
chiatric disorders, 6 were in a coma, 5 were not native
Dutch speaking, 9 were younger than 40 years, 9 lived too
far from the hospital, 6 were admitted too long after their
stroke and 35 declined participation) [17].
Patient characteristics at baseline (1 month after the
event) are presented in Table 2. During the follow-up, 54
patients dropped out (27 died, 24 patients refused further
participation, 1 patient was too ill at the 24-month follow-
up, and 2 were untraceable).
Drop-outs were older than non-drop-outs (75.4 and
65.8 years, respectively, p\0.001), had lower baseline
MMSE scores (24.1 and 26.0, respectively, p\0.001), and
were less educated (70.4 and 50.7% of patients were less
educated, respectively, p\0.001).
Table 3 shows the percentage of patients who deterio-
rated or improved at least in one domain of the cognitive
domains tested, compared to baseline at 12 and 24 month
Table 1 Cognitive domains
Domain Tests
Memory AVLT, total words direct recall and delayed recall
Mental speed SCWT I, CST 0,I, and II
Executive functioning Mean interference score SCWT, CST
Calculation GIT, sums
Visuospatial GIT, mental rotation
Orientation CAMCOG items 139–148 (place, person, time)
Attention CAMCOG items 178–179 (serial 7’s, counting backward)
Praxis CAMCOG items 183–186/188–189/191–193 (copying, ideational, ideomotor)
Reasoning CAMCOG items 197–200, 201–203 (similarities, perception)
Language CAMCOG items 149–163/181–182 (understanding, expression, writing)
AVLT Auditory Verbal Learning Test, SCWT Stroop Colour Word Test, CST Concept Shifting Test, GIT Groninger Intelligence Test
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123follow-ups. Patients were categorised into baseline MMSE
scores over 27, between 27 and 24, or lower than 24.
Patients with MMSE scores below 24 were older than
patients with scores higher than 27 (70.5 (SD 11.8) and
64.0 (SD 11.9) years, respectively, p = 0.04) and more
often less educated (70 and 39.4%, respectively, v
2 = 10.0,
df = 4, p = 0.04). After 12 months, most patients
improved or remained stable in number of cognitive
domains disturbed in each category of baseline MMSE
score. Patients with baseline MMSE scores lower than 24
more often deteriorated. Patients with higher baseline
MMSE scores more often were stable in the number of
cognitive domains disturbed (v
2 = 13.6, df = 4,
p = 0.009). After 24 months, measures were comparable.
Chi square tests between categories were not signiﬁcant.
There was no signiﬁcant difference in mean baseline
MMSE score, age, or educational level between patients
who deteriorated cognitively during follow-up and patients
who did not. These ﬁndings were comparable in patients
with left-sided lesions and right-sided lesions and in
demented and non-demented patients.
Baseline MMSE correlated well to scores on the MMSE
at later follow-up visits 6, 12, and 24 months: r = 0.77,
r = 0.76, and r = 0.73, respectively, (p\0.01).
TheMMSEscoreatbaselinerelatedwelltothenumberof
cognitive domains disturbed at baseline and at later follow-
up visits at 6, 12, and 24 months: r =- 0.68, r =- 0.70,
r =- 0.62, and r =- 0.69, respectively (p\0.01).
Table 4 shows the prevalence of patients suffering from
at least 4 disturbances in cognitive domains and the prev-
alence of patients with a maximum of 1 disturbance based
on their baseline MMSE score.
To study whether baseline MMSE could predict the
number of disturbed cognitive domains, multivariate
regression analysis was performed with adjustment for age,
sex and level of education. Baseline MMSE was a signif-
icant predictor for the number of disturbed cognitive
domains at baseline and later follow-up visits at 6, 12, and
24 months after the event (p\0.05). Furthermore, the
MMSE was a signiﬁcant predictor for the diagnosis of
dementia in the multivariate model (p\0.05).
Figure 1 shows the ROC of the MMSE in the screening
for a disturbance in cognitive domains and for the diag-
nosis of dementia.
At baseline, 163 patients suffered from at least 1 dis-
turbed domain out of 10 cognitive domains, 137 patients
from at least 2 and 85 patients suffered from at least 4
disturbed domains out of 10 cognitive domains. Table 5
shows optimum cut-off scores of the MMSE and their
sensitivity and speciﬁcity in the screening for cognitive
impairments and dementia.
Table 2 Demographic characteristics at baseline (1 month)
Total cohort Follow-up completed Drop-outs p*
N 194 140 54
Education (low) % 56.2 50.7 70.4 0.019
Sex (F) % 44.8 45.7 42.6
Age mean (SD) 68.3 (12.5) 65.8 (12) 74.6 (11.5) \0.000
Cortical lesion % 37.6 38.2 50.0
Left sided lesion % 42.1 39.6 52.8
Rankin mean (SD) 3.1 (1.4) 3.0 (1.3) 3.2 (1.4)
MMSE mean (SD) 25.5 (3.5) 26 (3.3) 24.1 (3.7) 0.002
Diagnosis of dementia at baseline % 11.4 7.9 20.4 0.02
Rankin: no handicaps: 0, bedridden: 5
SD standard deviation, MMSE Mini-Mental State Examination (minimum score: 0, maximum score: 30)
* p values for signiﬁcant differences in the comparison between patients who completed the follow-up and drop-outs are presented
Table 3 Patients who improved or deteriorated in cognitive func-





Baseline MMSE C 27 40.8 40.8 18.4
Baseline MMSE\27 and C24 65.6 18.8 15.6
Baseline MMSE\24 58.6 10.3 31.0
24 months
Baseline MMSE C 27 41.0 43.6 15.4
Baseline MMSE\27 and C24 52.9 32.4 14.7
Baseline MMSE\24 51.7 17.2 31.0
Numbers represent percentages
Change in cognitive functioning means an improvement or deterio-
ration of 1 in 10 previously described cognitive domains compared to
baseline
At 24 month follow-up, the number of patients followed -up com-
pletely with baseline MMSE C 27 was 78, MMSE\27 and C24 was
34, and for MMSE\24 was 29
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123In the screening for 1 impaired cognitive domain, we
found a moderate sensitivity of 0.72 at a cut-off score of
27/28. At a cut-off of 28/29, sensitivity increased to 0.87
but the speciﬁcity decreased to 0.42. These values were
comparable in patients with left-sided lesions and patients
with right-sided lesions.
To study whether baseline MMSE scores could predict
further deterioration or improvement in cognitive func-
tioning, correlations and regression analyses were per-
formed using the MMSE as a continuous scale, and after
categorising patients into baseline MMSE scores over 27,
between 27 and 24, or lower than 24. There was no cor-
relation between the baseline MMSE score and an
improvement or deterioration in cognitive functioning.
Neither could baseline MMSE scores predict an improve-
ment or deterioration in cognitive functioning in a multi-
variate regression model adjusted for age, sex and
education. A deterioration in MMSE score correlated with
deterioration in cognitive functioning over time.
Discussion
The aim of this study was to investigate whether, 1 month
after stroke, the MMSE could predict cognitive impairment
and its course over 2 years. We found signiﬁcant correla-
tions between the MMSE score 1 month after the event and
cognitive deﬁcits at each follow-up visit 6, 12, and
24 months after. Furthermore, the MMSE predicted cog-
nitive impairment and dementia in a multivariate regres-
sion model adjusted for age and education. These ﬁndings
are comparable to a study by Tatemichi and co-workers,
who found that poor performance on the MMSE after
1 week after stroke was an important indicator for poor
performance in cognitive functioning after 3 months [2].
After 1 year, about 60% of patients with baseline
MMSE scores less than 27 and 40% of those with MMSE
scores of at least 27 showed an improvement in their
cognitive performance. Patients with low MMSE scores
more often deteriorated, whereas patients with higher
scores more often were stable in the number of disturbed
cognitive domains. However, baseline MMSE scores were
not sensitive in screening for a change in cognitive per-
formance. Deterioration or improvement in the number of
disturbed cognitive domains at later follow-up visits was
not predicted by the MMSE 1 month after the event.
A deterioration in MMSE score correlated with deteriora-
tion in cognitive functioning in time.
We found MMSE cut-off scores of 27/28 showed a good
sensitivity in screening for at least 2 disturbed domains, as
did a cut-off of 26/27 in screening for at least 4 disturbed
domains. In the diagnosis for dementia, we found a cut-off
score of 23/24 with a sensitivity and speciﬁcity of 0.96 and
0.83, respectively. However, in screening for 1 disturbed
domain we found a cut-off score of 27/28 with a moderate
sensitivity and speciﬁcity of 0.72 and 0.71. The cut-off
scores in our study are comparable to those in the literature
Table 4 Percentages of patients with at least 4 cognitive domains
and 1 or fewer domains disturbed
Baseline 6 months 12 months 24 months
C4 domains disturbed
Baseline MMSE
\24 80 80.0 75.9 79.3
24 B MMSE\27 53.1 28.1 25.0 29.0
C27 14.1 4.0 10.5 7.7
B1 domains disturbed
Baseline MMSE
\24 6.7 3.3 17.2 10.3
24 B MMSE\27 9.4 25.0 46.9 29.0
C27 56.4 72.0 65.8 69.2
At baseline, the number of patients with an MMSE score\24 was 30,
with an MMSE score between 24 and 27 was 32, and with an MMSE
score C27 was 78
Only patients with complete follow-up (N = 140) were studied
Fig. 1 Receiver Operating Curves of the MMSE in the screening for
impaired cognitive domains and dementia
Table 5 Screening abilities of the MMSE at optimum cut-off points
in the screening for impaired cognitive domains and dementia
Impaired domains Cut-off Sensitivity Speciﬁcity PPV AUC
C1 27/28 0.72 0.71 0.93 0.79
C2 27/28 0.80 0.70 0.86 0.86
C4 26/27 0.82 0.75 0.72 0.88
Dementia 23/24 0.96 0.83 0.41 0.94
PPV positive predictive value, AUC area under the curve
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123[8, 22, 23]. Our results suggest that an MMSE score
of less than 27 possibly indicates substantial cognitive
disturbances and thorough screening for cognitive decline
is warranted. The MMSE is moderately sensitive in the
mildly cognitively affected patients.
The validity of the MMSE in screening for cognitive
decline and dementia in stroke is still debated in the lit-
erature [13, 20, 22]. It is said to be sensitive only when a
patient is already severely impaired [16]. In screening for
dementia in general, a cut-off of 23/24 is administered.
However, the literature advises adjusting this cut-off to an
individual patient’s confounders [24] or increasing the cut-
off value [23]. In our study, based on sensitivity at the
optimum cut-off points, the MMSE showed moderate
properties in screening for mild cognitive disturbances, but
was a sensitive tool in screening for moderate cognitive
deterioration and dementia.
Nys and co-workers studied the validity of the MMSE in
the ﬁrst week after stroke in screening for any disturbance
in 1 of 6 cognitive domains in 34 stroke patients and 34
age- and education-matched controls [20]. They could not
ﬁnd an optimum cut-off point in the screening for at least 1
out of 6 disturbed domains. Our study included a larger
sample and contained a comparable amount of subcortical
and cortical lesions. We did not examine the patients
cognitively in the ﬁrst days after stroke. The MMSE was
performed in the same session as the neuropsychological
test battery.
In another study comprising 112 stroke patients, the
MMSE had a moderate sensitivity (0.62) and speciﬁcity
(0.88) at a cut-off point of 24 in screening for cognitive
impairment [25]. The authors concluded that the MMSE is
not sensitive to memory complaints. Time between the
MMSE (ﬁrst week after stroke) and cognitive testing
(within 3 months after stroke) varied substantially. There-
fore, the relationship between the two may have been
weakened, since spontaneous recovery may have occurred
between tests.
Several studies report limitations of the MMSE in
screening for dementia and cognitive impairment, espe-
cially in subcortical infarctions and small vessel disease,
where it would not differentiate between focal and diffuse
lesions. Furthermore, it would be insensitive to right-sided
lesions [13–15]. We found no differences in screening
properties between patients with left-sided lesions and
those with right-sided lesions.
Other studies report the MMSE to be sufﬁciently accu-
rate as a screening instrument for cognitive impairment and
dementia in stroke patients in the clinical situation, and
support the ability of the MMSE to follow-up cognitive
performance over time [7, 9, 22, 26, 27]. Other studies
found the MMSE to be a useful screening tool when taking
confounders into account such as age and education [10,
12, 24, 28], or when another additional screening test is
performed [14, 29] and state that the difference in
screening ability between left and right-sided lesions is
exaggerated [12]. We found the MMSE to be an indepen-
dent predictor for cognitive functioning.
The standard criteria and the ease of use make the test
attractive [7, 30]. Furthermore, all short screening tests
share deﬁcits in sensitivity [31].
This study has some limitations to be mentioned. We
excluded a substantial number of patients with our exclu-
sion criteria. Our study was comprised of the relatively
cognitively better part of stroke patients, since patients
with severe aphasia and an MMSE score \15 were
excluded. However, this generally applies to follow-up
studies that require long-term cooperation. Patients are
required to understand the tasks to measure their cognitive
performance accurately. Including these patients would
have increased the relationship between the MMSE and
cognitive dysfunction, and would have improved the sen-
sitivity values in our study and the accuracy of the MMSE
in screening for cognitive impairment and dementia. It is
not conceivable that the exclusion of the other patients
inﬂuenced our results.
The 54 patients lost to follow-up were older, less
educated, and had more cognitive deﬁcits and lower
MMSE scores. This may have rather weakened our
results.
In the cross-sectional analyses we found that most
patients improved in cognitive functioning, and that
patients with low baseline MMSE scores deteriorated more
often than patients with high scores. These ﬁndings indi-
cate that there are some differences in cognitive function-
ing over time between patients with high and low MMSE
scores. However, neither in patients with high baseline
MMSE scores nor in patients with low scores is this a
linear effect predicted by baseline MMSE scores. Patients
with high baseline MMSE scores more often were stable in
their cognitive performance, whereas patients with low
baseline MMSE scores were less likely to stabilize and
showed a more dynamic course in improvement or dete-
rioration of cognitive performance. Moreover, a change in
cognitive functioning could not be predicted by the MMSE
scores in a regression model adjusted for age and educa-
tion. As is shown in this and other studies, it is conceivable
that a number of patients with cognitive impairment will
deteriorate and a number of patients will improve [32, 33].
Most improvement is seen in the ﬁrst months after stroke.
The cross-sectional measurements after 24 months will
partially overlap with those found at the 12-month visit.
Thus, although we analysed only patients from whom we
had test results at each follow-up visit, we cannot be pre-
cise in determining the temporal effect on cognitive func-
tioning in an individual patient and the relationship with
J Neurol (2010) 257:630–637 635
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linear mixed models analyses could be applied to analyse
the course of cognitive functioning in time. However, this
was problematic since drop-outs differed substantially in
demographics and in MMSE scores from patients who
completed the follow-up. A study of the risk factors for
decline was beyond our goals. Furthermore, our study was
focussed on validating the screening ability of the MMSE.
For this purpose, the utilisation of a fully completed data
set was preferred. Although we assessed pre-stroke cog-
nitive functioning in a retrospective manner by means of a
structured interview based on the DSM-IV criteria for
dementia with the patients’ caregiver, and not by means of
a measurement scale, we cannot precisely distinguish how
pre-stroke cognitive performance inﬂuences post-stroke
cognitive performance, cognitive recovery, or how stroke
inﬂuences pre-stroke cognition. To rule out such an effect,
for instance, the change in MMSE scores between 6- and
1-month visits could be used to predict further cognitive
change. However, this was beyond the goals of our study.
Studying the effects between pre-stroke cognitive perfor-
mance, stroke and post-stroke cognitive functioning would
require a different study design.
We did not adjust for age and education in calculating
the optimum cut-off. However, deﬁning confounding fac-
tors for the MMSE was beyond the aim of this study. In the
multivariable model, age and educational level did not
predict cognitive functioning, whereas the baseline MMSE
did.
Despite its limitations reported in the literature, we
found that the MMSE, which is easy to use, is a useful
instrument to screen for moderate to severe cognitive
deﬁcits in stroke patients and to screen patients for more
detailed neuropsychological assessment. A score on the
MMSE of\27 1 month after stroke is also related to poor
cognitive performance in the longer term. However, it
cannot be used to predict whether an individual patient will
recover or deteriorate.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Patel M, Coshall C, Rudd A et al (2003) Natural history of
cognitive impairment after stroke and factors associated with its
recovery. Clin Rehabil 17(2):158–166
2. Tatemichi TK, Desmond DW, Stern Y et al (1994) Cognitive
impairment after stroke: frequency, patterns, and relationship to
functional abilities. J Neurol Neurosurg Psychiatry 57(2):202–207
3. Aben I, Verhey F, Strik J et al (2003) A comparative study into
the one year cumulative incidence of depression after stroke and
myocardial infarction. J Neurol Neurosurg Psychiatry 74(5):581–
585
4. Heruti RJ, Lusky A, Dankner R et al (2002) Rehabilitation out-
come of elderly patients after a ﬁrst stroke: effect of cognitive
status at admission on the functional outcome. Arch Phys Med
Rehabil 83(6):742–749
5. Borjesson-Hanson A, Gustafson D, Skoog I (2007) Five-year
mortality in relation to dementia and cognitive function in 95-
year-olds. Neurology 69(22):2069–2075
6. Denti L, Agosti M, Franceschini M et al (2007) Outcome pre-
dictors of rehabilitation for ﬁrst stroke in the elderly. Eura
Medicophys 43:2–9
7. Rabadi MH, Rabadi FM, Edelstein L et al (2008) Cognitively
impaired stroke patients do beneﬁt from admission to an acute
rehabilitation unit. Arch Phys Med Rehabil 89(3):441–448
8. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state.
A practical method for grading the cognitive state of patients for
the clinician. J Psychiatr Res 12(3):189–198
9. Tombaugh TN, McIntyre NJ (1992) The mini-mental state
examination: a comprehensive review. J Am Geriatr Soc
40(9):922–935
10. Agrell B, Dehlin O (2000) Mini mental state examination in
geriatric stroke patients. Validity, differences between subgroups
of patients, and relationships to somatic and mental variables.
Aging (Milano) 12(6):439–444
11. Zwecker M, Levenkrohn S, Fleisig Y et al (2002) Mini-Mental
State Examination, cognitive FIM instrument, and the Loewen-
stein Occupational Therapy Cognitive Assessment: relation to
functional outcome of stroke patients. Arch Phys Med Rehabil
83(3):342–345
12. Appelros P (2005) Characteristics of Mini-Mental State Exami-
nation 1 year after stroke. Acta Neurol Scand 112(2):88–92
13. Dick JP, Guiloff RJ, Agron J et al (1984) Mini-Mental State
Examination in neurological patients. J Neurol Neurosurg Psy-
chiatry 47(5):496–499
14. O’Sullivan M, Morris RG, Markus HS (2005) Brief cognitive
assessment for patients with cerebral small vessel disease.
J Neurol Neurosurg Psychiatry 76(8):1140–1145
15. Fure B, Bruun Wyller T, Engedal K et al (2006) Cognitive impair-
ments in acute lacunar stroke. Acta Neurol Scand 114(1):17–22
16. Anthony JC, LeResche L, Niaz U et al (1982) Limits of the
‘Mini-Mental State’ as a screening test for dementia and delirium
among hospital patients. Psychol Med 12(2):397–408
17. Rasquin SM, Lodder J, Ponds RW et al (2004) Cognitive func-
tioning after stroke: a one-year follow-up study. Dement Geriatr
Cogn Disord 18(2):138–144
18. Jolles J, Houx PJ and van Boxtel MP (1995) The Maastricht
Aging Study: Determinants of cognitive aging. Neuropsychology
Publishers, Maastricht
19. Rasquin SM, Lodder J, Verhey FR et al (2005) The effect of
different diagnostic criteria on the prevalence and incidence of
post-stroke dementia. Neuroepidemiology 24(4):189–195
20. Nys GM, van Zandvoort MJ, de Kort PL et al (2005) Restrictions
of the Mini-Mental State Examination in acute stroke. Arch Clin
Neuropsychol 20(5):623–629
21. Petersen RC (2004) Mild cognitive impairment as a diagnostic
entity. J Intern Med 256(3):183–194
22. Feher EP, Mahurin RK, Doody RS et al (1992) Establishing the
limits of the Mini-Mental State. Examination of ‘subtests’. Arch
Neurol 49(1):87–92
23. Kukull WA, Larson EB, Bowen J et al (1994) The Mini-Mental
State Examination score and the clinical diagnosis of dementia.
J Clin Epidemiol 47(9):1061–1067
24. Crum RM, Anthony JC, Bassett SS et al (1993) Population-based
norms for the Mini-Mental State Examination by age and edu-
cational level. JAMA 269(18):2386–2391
636 J Neurol (2010) 257:630–637
12325. Blake H, McKinney M, Treece K et al (2002) An evaluation of
screening measures for cognitive impairment after stroke. Age
Ageing 31(6):451–456
26. Sachdev PS, Brodaty H, Valenzuela MJ et al (2004) Progression
of cognitive impairment in stroke patients. Neurology
63(9):1618–1623
27. Popovic IM, Seric V, Demarin V (2007) Mild cognitive impair-
ment in symptomatic and asymptomatic cerebrovascular disease.
J Neurol Sci 257(1–2):185–193
28. MacKenzie DM, Copp P, Shaw RJ et al (1996) Brief cognitive
screening of the elderly: a comparison of the Mini-Mental State
Examination (MMSE), Abbreviated Mental Test (AMT) and
Mental Status Questionnaire (MSQ). Psychol Med 26(2):427–
430
29. Suhr JA, Grace J (1999) Brief cognitive screening of right
hemisphere stroke: Relation to functional outcome. Arch Phys
Med Rehabil 80:773–776
30. Appelros P, Andersson AG (2006) Changes in Mini Mental State
Examination score after stroke: lacunar infarction predicts cog-
nitive decline. Eur J Neurol 13(5):491–495
31. Nelson A, Fogel BS, Faust D (1986) Bedside cognitive screening
instruments. A critical assessment. J Nerv Ment Dis 174(2):73–83
32. Riepe MW, Riss S, Bittner D et al (2004) Screening for cognitive
impairment in patients with acute stroke. Dement Geriatr Cogn
Disord 17(1–2):49–53
33. del Ser T, Barba R, Morin M et al (2005) Evolution of cognitive
impairment after stroke and risk factors for delayed progression.
Stroke 36(12):2670–2675
J Neurol (2010) 257:630–637 637
123